NRX Pharmaceuticals(NRXP)
$2.45+0.30 (+13.95%)
NRXP
NRX Pharmaceuticals financials statements
$2.45
At close:+0.30 (+13.95%)
Want to see NRXP full AI Analyst Report?
NRX Pharmaceuticals (NRXP) Ratios
1,029 Followers
NRX Pharmaceuticals Ratios
NRXP's free cash flow for Q2 2026 was $-9.77M. For the 2026 fiscal year, NRXP's free cash flow was decreased by $-897.00K and operating cash flow was $-8.88M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Mar 24 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.31 | 0.15 | 0.36 | 1.66 | 2.74 |
| Quick Ratio | 0.31 | 0.15 | 0.36 | 1.66 | 2.74 |
| Cash Ratio | 0.27 | 0.07 | 0.24 | 1.29 | 2.32 |
| Solvency Ratio | -0.99 | -0.93 | -1.58 | -2.16 | -7.81 |
| Operating Cash Flow Ratio | -0.49 | -0.49 | -1.14 | -2.55 | -3.16 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -6.79 | -2.36 | -5.16 | -72.79 |
| Net Current Asset Value | $ -20.00M | $ -23.57M | $ -12.16M | $ 7.39M | $ 20.79M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 1.80 | 1.25 | 0.41 | 0.02 |
| Debt-to-Equity Ratio | -0.04 | -0.28 | -0.78 | 1.42 | 0.02 |
| Debt-to-Capital Ratio | -0.04 | -0.40 | -3.56 | 0.59 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.28 | 0.00 | 0.28 | 0.00 |
| Financial Leverage Ratio | -0.81 | -0.16 | -0.62 | 3.48 | 1.57 |
| Debt Service Coverage Ratio | -41.44 | -9.09 | -3.24 | -5.16 | -173.59 |
| Interest Coverage Ratio | -24.18 | -18.26 | -229.89 | 0.00 | -5288.94 |
| Debt to Market Cap | 0.00 | 0.28 | 0.26 | 0.01 | 0.00 |
| Interest Debt Per Share | 0.06 | 0.73 | 1.23 | 0.16 | 0.01 |
| Net Debt to EBITDA | 0.26 | -0.21 | -0.15 | 0.24 | 0.29 |
| Profitability Margins | |||||
| Gross Profit Margin | 58.78% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -2281.71% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -2270.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -1324.41% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -2336.49% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -2336.49% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -2336.49% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 176.42% | 127.52% | 109.29% | 89.67% | 97.75% |
| Return on Assets (ROA) | -220.92% | -688.20% | -412.17% | -153.99% | -284.34% |
| Return on Equity (ROE) | 179.59% | 108.19% | 256.97% | -536.56% | -447.29% |
| Return on Capital Employed (ROCE) | 103.85% | 108.19% | 235.12% | -433.34% | -457.57% |
| Return on Invested Capital (ROIC) | 106.00% | 118.37% | 1072.59% | -247.21% | -446.45% |
| Return on Tangible Assets | -279.57% | -688.20% | -412.17% | -153.99% | -284.34% |
| Earnings Yield | -49.35% | -108.59% | -86.51% | -5.45% | -4.15% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.61 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | -0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3038.27 | -301490.00 | -338136.00 | -189435.00 | -672877.50 |
| Days of Sales Outstanding | 47.97 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 3086.24 | 301490.00 | 338136.00 | 189435.00 | 672877.50 |
| Operating Cycle | 47.97 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.66 | -1.01 | -2.86 | -0.60 | -0.80 |
| Free Cash Flow Per Share | -0.66 | -1.01 | -2.86 | -0.60 | -0.80 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -7219.00 | -3975.50 | -5386.14 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -7219.00 | -3975.50 | -5386.14 |
| Operating Cash Flow Coverage Ratio | -22.36 | -1.62 | -2.36 | -3.78 | -72.79 |
| Operating Cash Flow to Sales Ratio | -11.52 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -24.33% | -45.97% | -62.15% | -5.45% | -1.68% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.02 | -0.92 | -1.16 | -18.36 | -24.10 |
| Price-to-Sales (P/S) Ratio | 47.35 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -3.64 | -1.00 | -2.97 | 98.53 | 107.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.11 | -2.18 | -1.61 | -18.36 | -59.47 |
| Price-to-Operating Cash Flow Ratio | -4.11 | -2.18 | -1.61 | -18.36 | -59.48 |
| Price-to-Earnings Growth (PEG) Ratio | 0.05 | 0.02 | -0.00 | 0.20 | -0.06 |
| Enterprise Value Multiple | -1.83 | -1.18 | -1.31 | -18.13 | -23.81 |
| Enterprise Value | 50.83M | 28.27M | 39.42M | 720.48M | 2.22B |
| EV to EBITDA | -1.83 | -1.18 | -1.31 | -18.13 | -23.81 |
| EV to Sales | 41.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.60 | -2.66 | -1.82 | -18.12 | -58.75 |
| EV to Operating Cash Flow | -3.60 | -2.66 | -1.82 | -18.12 | -58.76 |
| Tangible Book Value Per Share | -0.87 | -2.21 | -1.55 | 0.11 | 0.44 |
| Shareholders’ Equity Per Share | -0.74 | -2.21 | -1.55 | 0.11 | 0.44 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.34 | -2.39 | -3.98 | -0.60 | -1.98 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.02 | 1.04 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 3.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 10.66 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.49 | 0.42 | 0.72 | 1.00 | 0.41 |
Currency in USD

